首页> 外文期刊>Technology in cancer research & treatment. >The Combined Antitumor Effects of 125 I Radioactive Particle Implantation and Cytokine-Induced Killer Cell Therapy on Xenograft Hepatocellular Carcinoma in a Mouse Model
【24h】

The Combined Antitumor Effects of 125 I Radioactive Particle Implantation and Cytokine-Induced Killer Cell Therapy on Xenograft Hepatocellular Carcinoma in a Mouse Model

机译:125酮放射性颗粒植入和细胞因子诱导杀手细胞疗法在小鼠模型中对异种移植肝细胞癌的组合抗肿瘤效应

获取原文
获取外文期刊封面目录资料

摘要

The combination of radiotherapy and immunotherapy has shown great promise in eradicating tumors. For example,125I radioactive particle implantation and cytokine-induced killer cell therapies have demonstrated efficacy in treating hepatocellular carcinoma. However, the mechanism of this combination therapy remains unknown. In this study, we utilized cytokine-induced killer cells obtained from human peripheral blood mononuclear cells along with125I radioactive particle implantation to treat subcutaneous hepatocellular carcinoma xenograft tumors in BALB/c nude mice. The effects of combination therapy on tumor growth, tumor cell apoptosis and proliferation, animal survival, and immune indexes were then assessed. The results indicated that125I radioactive particle implantation combined with cytokine-induced killer cells shows a much greater antitumor therapeutic effect than either of the therapies alone when compared to control treatments. Mice treated with a combination of radiotherapy and immunotherapy displayed significantly reduced tumor growth.125I radioactive particle implantation upregulated the expression of major histocompatibility complex (MHC) class I chain-related gene A in hepatocellular carcinoma cells and enhanced cytokine-induced killer cell-mediated apoptosis through activation of caspase-3. Furthermore, cytokine-induced killer cells supplied immune substrates to induce a strong immune response after125I radioactive particle implantation therapy. In conclusion,125I radioactive particle implantation combined with cytokine-induced killer cell therapy significantly inhibits the growth of human hepatocellular carcinoma cells in vivo and improves animal survival times through mutual promotion of antitumor immunity, presenting a promising therapy for hepatocellular carcinoma.
机译:放射疗法和免疫疗法的组合在根除肿瘤中表现出很大的希望。例如,125I放射性粒子植入和细胞因子诱导的杀手细胞疗法在治疗肝细胞癌中表明了疗效。然而,这种联合治疗的机制仍然未知。在该研究中,我们利用从人外周血单核细胞获得的细胞因子诱导的杀手细胞以及125I放射性颗粒植入,以治疗BALB / C裸鼠中的皮下肝细胞癌异种移植肿瘤。然后评估组合治疗对肿瘤生长,肿瘤细胞凋亡和增殖,动物存活和免疫指标的影响。结果表明,与对照处理相比,125I诱导的杀伤细胞联合细胞因子诱导的杀伤细胞的放射性粒子植入显示比单独的疗法更大的抗肿瘤治疗效果。用放射治疗和免疫疗法组合治疗的小鼠显着降低肿瘤生长.125i放射性颗粒植入上调了主要组织相容性复合物(MHC)I类链状相关基因A在肝细胞癌细胞中的表达,增强细胞因子诱导的杀手细胞介导的细胞凋亡通过激活Caspase-3。此外,细胞因子诱导的杀手细胞提供免疫底物以诱导125I后放射性颗粒植入治疗后的强烈免疫应答。总之,125i放射性粒子植入联合细胞因子诱导的杀手细胞疗法显着抑制体内人肝细胞癌细胞的生长,并通过相互促进抗肿瘤免疫力改善动物存活时间,提出了对肝细胞癌的有希望的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号